Sanofi-Aventis's Multaq prioritised by US FDA
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's NDA for its amiodarone follow-on drug candidate Multaq (dronedarone) for the prevention of cardiovascular events in patients with atrial fibrillation and atrial flutter has been granted priority review status by theUS FDA.